Abstract： Background:Low handgrip strength (HS) and declining gait speed (GS) are increasingly obvious with aging,requiring effective,and safe medication for treatment.Trimetazidine (TMZ) modified release tablets,a common anti-angina drug,has potential benefits for alleviating the condition,but this has not yet been fully studied and therefore is the aim of this study.Methods:This is a prospective randomized controlled study.Fifty-eight eligible patients will be randomly assigned to one of two study groups:TMZ group or control group.For the TMZ group,a dose of 35 mg of oral TMZ will be administered with a meal twice a day for 3 months,in addition to any conventional treatments for angina.Only conventional treatments for angina will be administrated in the control group.The primary outcome will be the 6-min walking distance and the secondary outcomes will be:muscle strength (HS and pinch strength),GS,muscle endurance (five times sit-to-stand test),balance maintenance (tandem standing test),and the frequency of angina per week.Additionally,body mass index,circumferences (biceps,waist,hip,and calf),albumin levels,and the score on a five-question scale for sarcopenia will be obtained during the study.Discussion:This study aims to evaluate the usefulness of TMZ in a population with poor muscle function.The results may provide an effective and safe medical treatment to people with low muscle strength or physical performance.